Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 501–600 of 1,001
Szydełko, J., Szydełko-Gorzkowicz, M., & Matyjaszek‐Matuszek, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173997 · Cited by 17
“To exclude hormonal hypersecretion of the pituitary adenoma, additional functional tests were performed, including screening for glucocorticoid excess with an overnight dexamethasone suppression test, assessing for macroprolactin and metoclopramide with a test in line with recommendations to rule out functional hyperp…”
MethodWilson, P. J., Williams, J. R., & Smee, R. I. (2014) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12257 · Cited by 17
Yi, N., Ji, L., Zhang, Q., Zhang, S., Liu, X., Shou, X., & Lü, B. (2018) · Endocrine · doi:10.1007/s12020-018-1652-y · Cited by 17
Calafato, S., Austin-Zimmerman, I., Thygesen, J. H., Sairam, M., Metastasio, A., Marston, L., Abad‐Santos, F., Bhat, A., Harju‐Seppänen, J., Irizar, H., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0142-9 · Cited by 19
“A diagnosis of hyperprolactinemia is made when serum prolactin levels exceed the upper limit of wellestablished ranges for particular age/sex groups [22].”
BackgroundAlam, S. K., Pandit, A., Wang, L., Farsani, S. S. M., Thiele, B., Manoj, P., Aubry, M. C., Verma, V., Rudin, C. M., Lo, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07693-y · Cited by 19
“Furthermore, the FDA-approved D 2 R agonist cabergoline reduces tumour size in prolactinoma, a non-cancerous adenoma of the pituitary gland which typically has high D 2 R expression [82, 83].”
Nappi, R. E., Ciaccio, S. D., & Genazzani, A. D. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1897783 · Cited by 17
“time 0, 15-20 and 30-40min) to account for pulsatility [4,13].”
BackgroundInfluentialPark, K., Park, K. H., Park, H. R., Lee, J. M., Kim, Y. H., Kim, D.-Y., Won, T., Kong, S. H., Kim, J. H., Shin, C. S., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e97 · Cited by 16
Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications
Biagetti, B., & Simó, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011247 · Cited by 19
“Current guidelines in prolactinoma management [96] strongly recommended DAs (preferably cabergoline) as the first line of treatment.”
BackgroundGong, X., Yang, Z., Yuan, H., Yang, K., Li, C., Feng, S., Zhang, M., Li, Z., Zhou, H., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.837025 · Cited by 16
“Prolactinoma, acromegaly, and Cushing disease were diagnosed as previously described (2, 24, 25).”
BackgroundZandbergen, I. M., Huntoon, K. M., White, T. G., Bakker, L. E. H., Verstegen, M. J. T., Ghalib, L. M., van Furth, W. R., Pelsma, I. C. M., Dehdashti, A. R., Biermasz, N. R., et al. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102919 · Cited by 20
Almalki, M., Alsuraikh, M. A., Almalki, E., Aziz, F., Almazrouei, R. A., Aldahmani, K. M., Alshahrani, F., Alaqeel, M., Mahzari, M. M., & Ekhzaimy, A. A. (2024) · Pituitary · doi:10.1007/s11102-024-01383-2 · Cited by 16
Brand, B. A., de Boer, J. N., Willemse, E. J. M., Weickert, C. S., Sommer, I. E., & Weickert, T. W. (2024) · Archives of Women s Mental Health · doi:10.1007/s00737-024-01491-9 · Cited by 19
“Furthermore, the determination of prolactin levels from our assays may have been influenced by venipuncture stress and the pulsatile nature of prolactin secretion (Melmed et al. 2011; Whyte et al. 2015).”
Androgens are Fundamental in the Maintenance of Male Sexual Health
Morales, Á. (2011) · Current Urology Reports · doi:10.1007/s11934-011-0202-4 · Cited by 16
Geographic variation in cost of care for pituitary tumor surgery
Lee, C. C., Kimmell, K. T., Lalonde, A., Salzman, P., Miller, M. C., Calvi, L. M., Manuylova, E., Shafiq, I., & Vates, G. E. (2016) · Pituitary · doi:10.1007/s11102-016-0738-x · Cited by 17
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide
Felker, J. T., Patterson, B., Wrubel, D. M., & Janss, A. J. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0159 · Cited by 16
Su, Y., Du, G., Shen, H., Wang, W., Bao, J., Aierken, A., Wang, B., Jiang, S., Zhu, J., & Gao, X. (2019) · Journal of International Medical Research · doi:10.1177/0300060519848916 · Cited by 16
“Patients who had normal prolactin levels without symptoms were judged to be in remission; patients who had higher levels of prolactin with symptoms, and whose tumor size could not be reduced by 50% under maximum tolerable doses of dopamine agonists, were judged to be resistant to treatment, as in a previous study.(10)”
BackgroundResultHypophysitis — new insights into diagnosis and treatment
Kluczyński, Ł., Gilis‐Januszewska, A., Rogoziński, D., Pantofliński, J., & Hubalewska–Dydejczyk, A. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2019.0015 · Cited by 23
Li, K., Zhang, J., Wang, X., Ye, X., & Zhao, Y.-L. (2019) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2019.1660369 · Cited by 16
Chanson, P., & Maiter, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00016-7 · Cited by 27
No evidence for prolactin’s involvement in the post-ejaculatory refractory period
Valente, S., Marques, T., & Lima, S. Q. (2021) · Communications Biology · doi:10.1038/s42003-020-01570-4 · Cited by 19
Guidelines in the management of CNS tumors
Redjal, N., Venteicher, A. S., Dang, D. D., Sloan, A. E., Kessler, R. A., Baron, R. R., Hadjipanayis, C. G., Chen, C. C., Ziu, M., Olson, J. J., et al. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03530-8 · Cited by 19
Ambulkar, S. S., Darves-Bornoz, A. L., Fantus, R. J., Wren, J. M., Bennett, N., Halpern, J. A., & Brannigan, R. E. (2021) · Urology · doi:10.1016/j.urology.2021.03.007 · Cited by 16
Rudman, Y., Duskin‐Bitan, H., Manisterski, Y., Pertzov, B., Akirov, A., Masri‐Iraqi, H., & Shimon, I. (2021) · Clinical Endocrinology · doi:10.1111/cen.14541 · Cited by 15
“Patients who did not normalise prolactin had annual imaging beyond 12 months of treatment, until prolactin normalisation and/or when significant tumour shrinkage was evident.(14,30) Additional imaging was performed according to the treating physician's decision.”
BackgroundMethodMild hyperprolactinemia in a couple: What impact on fertility?
Maiter, D. M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.04.002 · Cited by 21
Aetiologies of Hyperprolactinaemia: A retrospective analysis from a tertiary healthcare centre
Malik, A. A., Aziz, F., Beshyah, S., & Aldahmani, K. M. (2019) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2019.19.02.008 · Cited by 16
Huang, X., Ren, L., Hou, L., Fan, H., Wang, C., Wang, C., & Li, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112862 · Cited by 15
Cyclin A in nonfunctioning pituitary adenomas
Lamback, E. B., Guterres, A., Barbosa, M. Á., Lima, C. H. D. A., Silva, D. A., Camacho, A. H. D. S., Chimelli, L. M. C., Kasuki, L., & Gadelha, M. R. (2020) · Endocrine · doi:10.1007/s12020-020-02402-5 · Cited by 16
Theta oscillations in prolactinomas: Neurocognitive deficits in executive controls
Cao, C., Wen, W., Liu, B., Ma, P., Li, S., Xu, G., & Song, J. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102455 · Cited by 17
Kaka, N., Sethi, Y., Patel, N., Kaiwan, O., Al-Inaya, Y., Manchanda, K., & Uniyal, N. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101466 · Cited by 19
Peixe, C. R., Alexandre, M. I., Gomes, A. C., Nobre, E. L., Silva, A. L., Oliveira, T., Lopéz‐Presa, D., Faria, C. C., Miguéns, J., Bugalho, M. J., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01319-2 · Cited by 16
The shift of therapeutic strategy for prolactinomas: surgery as the first-line option
Wu, Z. B. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00953-5 · Cited by 15
“Comparing these consensus documents 1–3 , we find a gradual change in the perception of what treatment is appropriate.”
Thyroid impairment and male fertility: a narrative review of literature
Anelli, V., Gatta, E., Pirola, I., Delbarba, A., Rotondi, M., & Cappelli, C. (2024) · The Aging Male · doi:10.1080/13685538.2024.2310303 · Cited by 21
The LH:FSH Ratio in Functional Hypothalamic Amenorrhea: An Observational Study
Boegl, M. S., Dewailly, D., Marculescu, R., Steininger, J., Ott, J., & Hager, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051201 · Cited by 18
“The relevance of the prolactin level, which also affects metabolism, osmoregulation, immune function, behavior, and many more [38,39], needs to be elucidated in women with FHA in the future.”
BackgroundMon, S. Y., Alkabbani, A. G., Hamrahian, A. H., Thorton, J. N., Kennedy, L., Weil, R. J., Olansky, L., Doshi, K. B., Makin, V., & Hatipoğlu, B. (2012) · Pituitary · doi:10.1007/s11102-012-0450-4 · Cited by 15
“In clinical practice, elevated prolactin levels without evidence of hypogonadism, galactorrhoea, or a mass have not been an indication for medical or surgical treatment [4, 14].”
BackgroundPituitary metastasis of lung neuroendocrine carcinoma: case report and literature review
de Siqueira, P. F., Mathez, A. L. G., Pedretti, D. B., & Abucham, J. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000139 · Cited by 15
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
Raveendranthan, D., Rao, N. P., Rao, M. G., Mangot, A. G., Varambally, S., Kesavan, M., Venkatasubramanian, G., & Gangadhar, B. N. (2018) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_147_17 · Cited by 15
“In suspected cases of psychotropic-induced hyperprolactinemia, the Endocrine Society guidelines suggest drug discontinuation for 3 days or substituting with an alternative drug and then remeasuring prolactin.([5]) Lu et al.”
BackgroundKrysiak, R. G., Szkróbka, W., & Okopień, B. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1301 · Cited by 15
“At the beginning of the study 86 (15) 88 (18) 91 (22)”
InfluentialDiamanti‐Kandarakis, E., Duntas, L. H., Kanakis, G., Kandaraki, E., Karavitaki, N., Kassi, E. N., Livadas, S., Mastorakos, G. P., Migdalis, I. N., Miras, A. D., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0154 · Cited by 16
Pathology of prolactinomas: any predictive value?
Lopes, M. B. S. (2019) · Pituitary · doi:10.1007/s11102-019-00997-1 · Cited by 15
MicroRNA-7a2 Regulates Prolactin in Developing Lactotrophs and Prolactinoma Cells
LaPierre, M. P., Godbersen, S., Esteban, M. T., Schad, A. N., Treier, M., Ghoshdastider, U., & Stoffel, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa220 · Cited by 15
Tao, J., Gong, X., Cao, Y.-L., Zhang, Q., Jing, S.-S., Wang, H., & Chen, Y. (2021) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2021.101322 · Cited by 15
What to Do with Incidentally Discovered Pituitary Abnormalities?
Langlois, F., & Fleseriu, M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.015 · Cited by 17
Haider, S. A., Levy, S., Rock, J. P., & Craig, J. R. (2022) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.12.005 · Cited by 15
Andersen, I. B., Sørensen, M. G. R., Doğanşen, S. Ç., Ku, C. R., Vilar, L., Feldt‐Rasmussen, U., & Krogh, J. (2022) · Clinical Endocrinology · doi:10.1111/cen.14714 · Cited by 16
“A more recent guideline from the Endocrine Society suggested that DA can be withdrawn following 2 years of treatment, normalized prolactin, and no visible tumour on MRI, although these recommendations were based on very low quality evidence.(3) Previous systematic reviews assessing the effect of dopamine agonist withd…”
BackgroundInfluentialTransnasal Transsphenoidal Surgical Method in Pediatric Pituitary Adenomas
Taşkapılıoğlu, M. Ö., Yılmazlar, S., Eren, E., Tarım, Ö., & Guler, T. M. (2015) · Pediatric Neurosurgery · doi:10.1159/000381862 · Cited by 15
Wilson, P. J., Williams, J. R., & Smee, R. I. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.12.026 · Cited by 15
“As with most other pituitary adenomas (the exception being prolactinomas primarily managed medically [7]), the primary management of Nelson’s syndrome has been reported to be more safe and effective with surgical intervention [8].”
BackgroundPregnancy in multiple endocrine neoplasia type 1 equals multiple complications
Mistry, M., Gupta, M., & Kaler, M. K. (2014) · Obstetric Medicine · doi:10.1177/1753495x14532634 · Cited by 15
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas
Akirov, A., Greenman, Y., Gläser, B., S’chigol, I., Mansiterski, Y., Eizenberg, Y., Shraga-Slutzky, I., & Shimon, I. (2018) · Pituitary · doi:10.1007/s11102-018-0891-5 · Cited by 15
Kim, K., Park, Y. W., Kim, D., Ahn, S. S., Moon, J. H., Kim, E. H., Lee, E. J., & Ku, C. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa744 · Cited by 15
Mangili, F., Treppiedi, D., Catalano, R., Marra, G., Muro, G. D., Spada, A., Arosio, M., Peverelli, E., & Mantovani, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.611752 · Cited by 15
Glezer, A., & Bronstein, M. D. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002961 · Cited by 22
Mehta, G. U., & Jane, J. A. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283587bed · Cited by 15
Lania, A. G., & Beck‐Peccoz, P. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.009 · Cited by 15
Scudder, C., Hazuchova, K., Gostelow, R., Church, D. B., Forcada, Y., Fowkes, R. C., & Niessen, S. (2020) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x20933213 · Cited by 14
Ceccato, F., Lizzul, L., Voltan, G., Barbot, M., & Scaroni, C. M. (2021) · Pituitary · doi:10.1007/s11102-021-01165-0 · Cited by 15
Şahin, S., Sudutan, T., Kavla, Y., Durcan, E., Özogul, Y. Y., Poyraz, B. Ç., Sayitoğlu, M., Özkaya, H. M., & Kadıoğlu, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac718 · Cited by 17
Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile?
Niculescu, D., Gheorghiu, M. L., & Poiană, C. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad044 · Cited by 18
Giant prolactinomas, a detailed analysis of 196 adult cases
Billion, L., Verleye, A., Block, C. E. M. D., de Heyning, P. V., & Herdt, C. D. (2023) · Pituitary · doi:10.1007/s11102-023-01337-0 · Cited by 17
Systematic review of the association between thyroid disorders and hyperprolactinemia
Khan, A. A., Sharma, R., Ata, F., Khalil, S. K., Aldien, A. S., Hasnain, M. F., Sadiq, A., Bilal, A. B. I., & Mirza, W. (2025) · Thyroid Research · doi:10.1186/s13044-024-00214-7 · Cited by 18
Treatment of the Hypogonadal Infertile Male—A Review
Ho, C. C. K., & Tan, H. M. (2013) · Sexual Medicine Reviews · doi:10.1002/smrj.4 · Cited by 16
Prevalence of subclinical and overt hypothyroidism in infertile women
Pushpagiri, N., Gracelyn, L., & Nagalingam, S. (2015) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20151214 · Cited by 16
Lee, J. Y., Park, J. E., Shim, W. H., Jung, S. C., Choi, C. G., Kim, S. J., Kim, J. H., & Kim, H. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187989 · Cited by 14
Incidental Findings on Brain Magnetic Resonance Imaging (MRI) in Pediatric Endocrine Patients
Brener, A., Kozyrev, D. A., Shiran, S. I., Azoulay, E., Pratt, L., Precel, R., Ben‐Sira, L., Eyal, O., Constantini, S., Roth, J., et al. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0208 · Cited by 14
Nguyen, K. Q., Langevin, R. H., McPhaul, M. J., & Hashim, I. A. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.018 · Cited by 14
Cidade-Rodrigues, C., Cunha, F. M., Chaves, C., Silva-Vieira, M., Silva, A., Garrido, S., Martinho, M., & de Almeida, M. F. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000133 · Cited by 14
“Among the most common drugs interfering with the production, transport and/or action of dopamine are antipsychotics, antidepressants and oestrogen therapy.(8)”
BackgroundHypophysitis: A comprehensive overview
de Vries, F., van Furth, W. R., Biermasz, N. R., & Pereira, A. M. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104076 · Cited by 14
Najafabadi, A. H. Z., van der Meulen, M., Zurita, A. L. P., Ahmed, S. F., van Furth, W. R., Charmandari, E., Hiort, O., Pereira, A. M., Dattani, M., Vitali, D., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0349 · Cited by 16
Prolactinomas in adolescent and elderly patients—A comparative long-term analysis
Andereggen, L., Tortora, A., Schubert, G. A., Musahl, C., Frey, J., Luedi, M. M., Mariani, L., Beck, J., & Christ, E. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.967407 · Cited by 15
Ovarian tumor-derived ectopic hyperprolactinemia
Elms, A. F., Carlan, S. J., Rich, A. E., & Cerezo, L. (2011) · Pituitary · doi:10.1007/s11102-011-0366-4 · Cited by 14
“functioning pituitary macroprolactinoma [3].”
BackgroundLong-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Khare, S., Lila, A. R., Patil, R., Phadke, M. S., Kerkar, P. G., Bandgar, T., & Shah, N. S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196010 · Cited by 14
“[3] Whereas the endocrine society guideline suggests that 2D echo may be required for those on high‐dose cabergoline therapy (>3 mg/week).[4]”
Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes
Rutkowski, M. J., & Aghi, M. K. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1411798 · Cited by 14
“higher levels may warrant screening [20].”
Evolution of macroprolactinomas during pregnancy: A cohort study of 85 pregnancies
Barraud, S., Guédra, L., Delemer, B., Raverot, G., Ancelle, D., Fèvre, A., Jouanneau, E., Litré, C., Wolak‐Thierry, A., Borson‐Chazot, F., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14162 · Cited by 16
Association Between Antipsychotics and Osteoporosis Based on Real-World Data
Yokoyama, S., Wakamoto, S., Tanaka, Y., NAKAGAWA, C., Hosomi, K., & Takada, M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020913974 · Cited by 16
Accornero, S., Danesino, C., Bastianello, S., D’Errico, I., Guala, A., & Chiovato, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0621 · Cited by 14
Faje, A. T., Jones, P. S., Swearingen, B., & Tritos, N. A. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.013 · Cited by 13
Fahie‐Wilson, M. N., Cobbaert, C. M., Horvath, A. R., & Smith, T. P. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0460 · Cited by 14
Clinical guidelines ‘Hyperprolactinemia’ (draft)
Dedov, I. I., Mel'nichenko, G. A., Dzeranova, L. K., Andreeva, E. N., Grineva, E. N., Marova, E. I., Mokrysheva, N. G., Pigarova, E. A., Vorotnikova, S. Y., Fedorova, N. S., et al. (2023) · Obesity and metabolism · doi:10.14341/omet13002 · Cited by 20
Vroonen, L., Beckers, A. M., Camby, S., Cuny, T., Beckers, P., Jaffrain‐Rea, M., Cogne, M., Naves, L. A., Ferrière, A., Romanet, P., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1242588 · Cited by 13
Pediatric pituitary neuroendocrine tumors–a 13-year experience in a tertiary center
Li, X., Deng, K., Zhang, Y., Feng, M., Xing, B., Lian, W., & Yao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1270958 · Cited by 16
Prolactin levels in functional hypothalamic amenorrhea: a retrospective case–control study
Selzer, C., Ott, J., Dewailly, D., Marculescu, R., Steininger, J., & Hager, M. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07277-1 · Cited by 14
“Risk factors for hyperprolactinemia that we know so far include physiological (lactation, pregnancy, sleep, stress), pathological (hypothalamic/pituitary damage, prolactinoma, systemic disorders) or iatrogenic (pharmacological, surgery) causes [12].”
BackgroundInfluentialCastro, M. A., Torre, E. L. M., Lozano-Aida, C., García-Centeno, R., Fernández, L. G., Idrobo, C., Achote, E., Irigaray, A., Rodríguez, M. D. M., Paja, M., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf252 · Cited by 14
Pituitary Incidentaloma: to Operate or Not to Operate ?
Donckier, J. E., & Gustin, T. (2012) · Acta chirurgica Belgica · doi:10.1080/00015458.2012.11680835 · Cited by 13
“This pitfall can be avoided by diluting the serum 1:100 (2, 24).”
BackgroundExpression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas
Gao, Z., Cai, L., Lu, J., Wang, C., Li, Q., Chen, J., Song, X., Chen, X., Zhang, L., Zheng, W., et al. (2017) · Medical Science Monitor · doi:10.12659/msm.901154 · Cited by 13
“Tumor recurrence after withdrawal of DAs is a key clinical concern in treatment of prolactinomas [4,31].”
BackgroundKrysiak, R. G., Szkróbka, W., & Okopień, B. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.004 · Cited by 14
Evaluation and management of amenorrhea related to congenital sex hormonal disorders
Yoon, J. Y., & Cheon, C. K. (2019) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2019.24.3.149 · Cited by 17
Zhang, D., Yuan, X., Zhen, J., Sun, Z., Deng, C., & Yu, Q. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00584 · Cited by 13
Aging and sex hormones in males
Decaroli, M. C., Vincentis, S. D., & Rochira, V. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.014 · Cited by 18
Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience
Lasolle, H., Teulade, M., Lapras, V., Vasiljevic, A., Borson‐Chazot, F., Jouanneau, E., & Raverot, G. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.11.008 · Cited by 13
Macroprolactin: From laboratory to clinical practice
Biagetti, B., Ferrer, R., Guerra, R. A., García, E. Á., Berlanga, E., Casals, G., Salán, M. E., Granada, M. L., Ramos, J. G., Lazareno, N. L., et al. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.01.001 · Cited by 29
Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
Zhu, C., Li, R., Ju, M., Xiao, X., Yuan, T., Jin, Z., & Zhao, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.892477 · Cited by 13
Giant prolactinoma in children and adolescents: a single-center experience and systematic review
Kumar, S., Sarathi, V., Lila, A. R., Sehemby, M., Memon, S. S., Karlekar, M. P., Sankhe, S., Patil, V. A., Shah, N. S., & Bandgar, T. (2022) · Pituitary · doi:10.1007/s11102-022-01250-y · Cited by 14
“We noted serum prolactin level was ≥ 1000 ng/ml (median: 8649 ng/ml) in all young patients except three who had a value of ≥ 500 ng/ml, a diagnostic cut-off for macroprolactinoma as suggested by Endocrine Society guidelines [23].”
BackgroundThe Role of Aromatase Inhibitors in Male Prolactinoma
Akirov, A., & Rudman, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041437 · Cited by 16
“In such tumors, additional treatment modalities may be required, including neurosurgery, radiotherapy, and/or temozolomide [3,29].”
BackgroundMethodInfluentialEffect of prolactin on cytotoxicity and oxidative stress in ovine ovarian granulosa cells
Yang, R., Zhang, S., Duan, C., Guo, Y., Shan, X., Zhang, X., Yue, S., Zhang, Y., & Liu, Y. (2023) · PeerJ · doi:10.7717/peerj.15629 · Cited by 13
“The normal serum PRL levels in females, depending on reference values, range from nearly 2 to 25 ng/mL (average 13 ng/ml) (Melmed et al., 2011).”
BackgroundACR Appropriateness Criteria® Infertility
Wall, D. J., Javitt, M. C., Glanc, P., Bhosale, P., Harisinghani, M. G., Harris, R. D., Khati, N. J., Mitchell, D. G., Nyberg, D. A., Pandharipande, P. V., et al. (2015) · Ultrasound Quarterly · doi:10.1097/ruq.0000000000000132 · Cited by 14
“Patients with galactorrhea and an elevated prolactin level and no other identifiable cause should undergo imaging evaluation for a sellar or suprasellar mass, including prolactinomas, macroadenomas, lymphocytic hypophysitis, granulomas, Rathke cleft cysts, and other suprasellar masses.(97) Adenomas are the most common…”
BackgroundVedin, A. M., Garcia‐Filion, P., Fink, C., Borchert, M., & Geffner, M. E. (2012) · Hormone Research in Paediatrics · doi:10.1159/000338330 · Cited by 13
“Mild hyperprolactinemia can occur in subjects with hypothalamic and/or pituitary stalk dysfunction [11], and is often seen in subjects with ONH [4,6].”
BackgroundElenkova, A. P., Pétrossians, P., Zacharieva, S., & Beckers, A. M. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.10.008 · Cited by 13
Chen, Y., Wang, H., Yang, W., Jin, W., Yu, W., Wang, W., Zhang, K., & Song, G. (2016) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21999 · Cited by 13
“0 ng/ml) (13) were admitted into our hospital, with an age range 11–55 years and a median age of 28 years.”
BackgroundNational consensus on the management of patients with hyperprolactinemia (2016)
Tronko, M. D., Антипкін, Ю. Г., Володимирович, К. В., & Татарчук, Т. Ф. (2016) · Reproductive Endocrinology · doi:10.18370/2309-4117.2016.30.8-18 · Cited by 15
Guidelines for Antipsychotic-Induced Hyperprolactinemia
Miyamoto, B. E., Galecki, M., & Francois, D. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150501-09 · Cited by 13
Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report
Satō, H., Asami, Y., Shiro, R., Yasuda, M., Imai, S., Sakai, R., Oida, K., Kawaharamura, K., Taguchi, N., Suzuki, T., et al. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1379501 · Cited by 13
“nancy is a pituitary prolactinoma [1,2].”
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.